Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4
and COX-2 mRNA and protein levels through inhibition of c-Jun N-terminal kinase and nuclear factor-kB in endothelial cells
P2X3 receptor is a promising target for therapeutic intervention in cancer patients for pain management
45(2):499-508
The MPC inhibitor UK5099 increases the glucose excursion seen during an intraperitoneal glucose tolerance test in C57BLK mice
Nilotinib - CAS# 641571-10-0 Catalog No.:M10937-10 and COX-2 mRNA and proteinNilotinib, also known as AMN107, is a small molecule tyrosine kinase inhibitor approved for the treatment of imatinib resistant chronic myelogenous leukemia. Structurally related to imatinib, it was developed based on the structure of the Abl imatinib complex to address imatinib intolerance and resistance. Nilotinib is a selective Bcr Abl kinase inhibitor that is 10 30 fold more potent than imatinib in inhibiting Bcr Abl tyrosine kinase activity and